AbbVie (ABBV) and Gubra announced a license agreement to develop GUB014295, a long-acting amylin analog for the treatment of obesity. Under the terms of the agreement, AbbVie will lead development ...

NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume ...

AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...

BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra announced a license agreement to develop GUB014295 ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb. 14. That is almost 6% higher than the prior payout. The company ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie ABBV in the last three months. The table below provides a concise overview of recent ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...